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Summary
The carnitine-acylcarnitine carrier (CAC) catalyzes the
translocation of long-chain fatty acids across the inner
mitochondrial membrane. We cloned and sequenced the
human CAC cDNA, which has an open reading frame
of 903 nucleotides. Northern blot studies revealed dif-
ferent expression levels of CAC in various human tissues.
Furthermore, mutation analysis was performed for a
CAC-deficient infant. Direct sequencing of
the patient’s cDNA revealed a homozygous cytosine nu-
cleotide insertion. This insertion provokes a frameshift
and an extension of the open reading frame with 23
novel codons. This is the first report documenting a mu-
tation, in the CAC cDNA, responsible for mitochondrial
b-oxidation impairment.
Introduction
The carnitine-acylcarnitine carrier (CAC) shuttles acyl-
carnitine esters, in exchange for free carnitine, across the
inner mitochondrial membrane (Pande 1975; Ramsay
and Tubbs 1975). This transport is an essential step in
the process of long-chain fatty-acid oxidation (Stanley
1987; Coates and Tanaka 1992; Stanley et al. 1992).
The oxidation of fatty acids in mitochondria plays an
important role in energy production. During fasting,
fatty acids are used for hepatic ketone-body synthesis.
Furthermore, fatty acids are an important source of en-
ergy for heart muscle and also for skeletal muscle, during
exercise, whereas ketone bodies are excellent substrates
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for the brain (Stanley 1987; Coates and Tanaka 1992).
The overall fatty-acid oxidation in mitochondria re-
quires the concerted action of at least 17 different pro-
teins, including 16 enzymes and the transporter CAC.
Genetic defects have been identified in most of these
proteins (Stanley 1987; Stanley et al. 1992). These de-
fects generally present in early infancy, with acute, po-
tentially life-threatening episodes of hypoketotic hypo-
glycemic coma induced by fasting. The clinical
phenotypes are very similar and can be attributed to one
of three major types of presentation, with predominantly
hepatic, cardiac, or skeletal muscle involvement (Kelly
and Strauss 1994; Pande andMurthy 1994; Pollit 1995).
So far, six cases of CAC deficiency have been reported
(Stanley et al. 1992; Pande et al. 1993; Brivet et al. 1994,
1996; Niezen-Koning et al. 1995; Ogier de Baulney et
al. 1995). The main features in these severely affected
patients with onset in the neonatal period are hypoke-
totic hypoglycemia, mild hyperammonemia, variable di-
carboxylic aciduria, hepatomegaly with abnormal liver
functions, various cardiac symptoms, and skeletal mus-
cle weakness. In all cases, CAC activity in cultured skin
fibroblasts is below detectable levels. However, so far,
the CAC deficiency has not been characterized at the
molecular level, in any patient.
Fundamental properties of eukaryotic CAC have been
investigated extensively in intact mitochondria (Pande
1975; Ramsay and Tubbs 1975; Pande and Parvin 1980;
Idell-Wenger 1981; Murthy and Pande 1984) and after
purification and reconstitution into liposomes (Indiveri
et al. 1990, 1991a, 1991b, 1992, 1994, 1995). The car-
rier is embedded in the inner mitochondrial membrane
and has an apparent molecular mass of 32.5 kD in rat
liver (Indiveri et al. 1990). It governs a one-to-one
exchange, between long-chain acylcarnitine esters and
nonesterified carnitine, across the inner mitochondrial
membrane and also the unidirectional transport of car-
nitine across this membrane, although less efficiently
(Pande and Parvin 1980; Indiveri et al. 1991a). Incor-
porated into liposomes, the purified carrier protein has
substrate specificity and inhibitor sensitivities similar to
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Figure 1 Nucleotide sequence of human CAC cDNA. The de-
duced amino acid sequence of the open reading frame of 903 bp (301
codons) is shown below the nucleotide sequence. Human CAC amino
acids that differ from those of rat CAC (Indiveri et al. 1997) are shown
in underlined, italicized print. The cDNA and deduced protein
sequences are in GenBank (accession no. Y10319; http://
www.ncbi.nhm.nih.gov/Web/Genbank/index.htm).
those in intact mitochondria (Indiveri et al. 1990, 1991a,
1991b). CAC operates according to a ping-pong mech-
anism (Indiveri et al. 1994).
Very recently we described the cDNA and amino acid
sequence of the rat CAC (Indiveri et al. 1997). These
studies have shown that CAC belongs to a protein family
that, so far, has been found to comprise 10 biochemically
well-characterized mitochondrial carriers and also sev-
eral other members of unknown function that are be-
ginning to emerge with the advance of genomic DNA
sequencing (Walker and Runswick 1993; Palmieri 1994;
Crabeel et al. 1996; Palmieri et al. 1996). These proteins
have evolved from a common ancestor, by two-tandem
gene duplication, and have related structures and mech-
anisms (Walker and Runswick 1993; Palmieri 1994).
We report on the nucleotide sequence of the human
CAC cDNA and the corresponding amino acid sequence,
as well as the distribution of CAC mRNA in human
tissues. For the first time, a mutation has been found in
the CAC cDNA of a unique, now 9-year-old, CAC-de-
ficient patient.
Patient and Methods
Case Report
This 9-year-old girl with a normal family history sur-
vived a severe neonatal condition consisting of hypo-
glycemia, cardiac arrest, hepatomegaly, and hepatic dys-
function. These features are often observed in patients
with a fatty-acid oxidation disorder. Thereafter episodes
of lethargy and hepatomegaly occurred only during mild
viral infections. Acylglycines were nondiagnostic, and
acylcarnitines showed increased medium- to long-chain
hydroxy and unsaturated derivatives. A liver biopsy
showed fatty infiltration. During the last few years, she
has had a rather normal physical and neurophysiological
development: she has done well with prolonged exercise,
and in between the attacks she is an alert, cooperative,
and pleasant young girl. Her symptoms are much milder
than those in the other CAC-deficient patients who have
been described. Cultured skin fibroblasts were sent to
one of us (R.W.) to investigate a possible defect in mi-
tochondrial fatty-acid oxidation.
Fibroblast Study
Overall b-oxidation in fibroblasts was measured as
described previously by Olpin et al. (1992). The CAC
activity in fibroblasts was measured essentially according
to the study by Pande et al. (1993).
Cloning and Sequencing of the Human CAC
Oligonucleotides were designed on the basis of the
cDNA sequence of the rat liver CAC (Indiveri et al.
1997), at the following nucleotide positions: 125–150
(sense 1F, 5′-CCTGGTGTTTGTGGGGCACCCCTTG-
3′); 455–480 (antisense 1R, 5′-CTGAATCTGCAG-
TAAGCATTTGATC-3′); 405–430 (sense 2F, 5′-GGG-
ATGTTATCTGGTGTGTTCACCA-3′); and 937–962
(antisense 2R, 5′-ACAAGTTGGGGGCAATCCAATT-
GAG-3′). These primers (Pharmacia Biotech) were used
in PCRs, to amplify cDNA fragments encoding the hu-
man liver CAC. The template was first-strand cDNA
reverse transcribed, with oligo(dT) by AMV reverse
transcriptase (Boehringer Mannheim) for 1 h at 55C,
from human liver mRNA (Clontech). PCR reactions
were carried out for 30 cycles (94C for 30 s, 60C for
1 min, and 72C for 2 min). At the end, a single incu-
bation at 72C for 7 min was added. The extension to
the 3′ end was performed by priming from poly(A), with
two nested forward primers (AGAAGAAGGAGTCA-
CCTCCTTGTA and CAAAGGGTTCAATGCAGTCA-
TGA, corresponding to nucleotides 831–854 and
855–877, respectively, of the rat cDNA sequence). To
extend the sequence to the 5′ end, a touchdown PCR
(Don et al. 1991) was performed on an adaptor-ligated
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Figure 2 Expression of CACmRNA in human tissues. Northern
blots (2 mg poly[A] RNA/tissue) hybridized with a human CAC probe
(A) and an actin probe (B) are shown. The molecular weight is indi-
cated in the figure: human CAC mRNA is ∼1.8 kb. Results for the
following tissues are shown: heart (H), brain (B), placental (P), lung
(Lu), liver (L), skeletal muscle (SM), kidney (K), and pancreatic (Pa).
double-stranded human liver cDNA (Clontech). In
this case we employed two nested forward adaptor prim-
ers and two reverse-specific primers (TTGTGTCTG-
CAGTCGGACCTTGAC and CCAGAGGGTGACCG-
ACGAACACCAGGC, corresponding to nucleotides
257–278 and 121–146, respectively, of the rat cDNA
sequence). DNA-sequence analysis was performed ac-
cording to established procedures (Indiveri et al. 1997).
Northern Blot Analysis
The sequence corresponding to nucleotides 421–967
of the human CAC cDNA was used as a probe in north-
ern blots performed on mRNA derived from various
human tissues (Clontech). Northern blot analysis was
performed according to standard protocols, with high
stringency. The filters were autoradiographed at80C.
For normalization of the hybridization signals a probe
encoding part of human actin (Clontech) was employed.
Mutation Detection
Total RNA was extracted (Chomczynski and Sacchi
1987) from cultured skin fibroblasts and was stored as
an ethanol precipitate at80C. A 5-mg sample of RNA
was reverse transcribed to cDNA, in 1 h at 42C, with
200 U of Superscript II reverse transcriptase (Life Tech-
nologies), by use of oligo(dT) and random hexamer
primers. Five microliters of this first-strand cDNA was
subjected to PCR amplification. By PCR, we generated
three overlapping fragments that covered the entire cod-
ing region, using the following synthetic oligonucleotide
primers (Perkin Elmer): for fragment 1, 5′-GCAGGT-
CGAGAACTGACAGAC-3′ (sense F1) and 5′-TTTCTC-
CTGAAGAAGCCTGAA-3′ (antisense R1), at positions
21–41 and 481–501, respectively, of the human CAC
cDNA sequence (fig. 1); for fragment 2, 5′-CCTGGA-
GAACGGATCAAGTG-3′ (sense F2) and 5′-CAATTA-
AGGAACTTCATGGCAA-3′ (antisense R2), at posi-
tions 450–469 and 928–949, respectively; and,
for fragment 3, 5′-GCAGTGATGATCCGAGCCTTC-3′
(sense F3) and 5′-ACAGGTAGTATCTGGTCTGGAA-
3′ (antisense R3), at positions 873–893 and 1224–1245,
respectively. For each fragment, 35 cycles of PCR were
performed (92C for 60 s, 60C for 60 s, and 72C for
90 s). The cycles were preceded by an initial denatura-
tion step at 95C for 3 min and were followed by a final
extension at 72C for 10 min. Ten microliters of each
PCR reaction was analyzed on 1.0% agarose gels with
0.5 mg ethidium bromide/ml in 1# Tris borate–EDTA.
The nucleotide sequences of the PCR products were an-
alyzed by direct sequencing using the Taq Dye Deoxy
Terminator Cycle Sequencing Kit (Applied Biosystems),
according to the manufacturer’s recommendations.
Results
Cloning and Sequencing of Human CAC cDNA
The recently reported rat cDNA of CAC (Indiveri et
al. 1997) was used for cloning and sequencing of the
human CAC homologue. Four overlapping sequences
were amplified, by PCR using human liver cDNA as a
template, with synthetic oligonucleotide primers based
on the rat cDNA sequence and, to extend the sequence
to the 5′ end, with two nested forward primers comple-
mentary to adaptors that were added to the 5′ extremities
of the human liver cDNA. The obtained cDNA sequence
was 1,243 bp in length and had an open reading frame
of 903 bp (fig. 1). Assignment of position 63 as the first
nucleotide of the initiation codon was deduced from
comparison with the CAC cDNA of rat liver (Indiveri
et al. 1997), since no stop codon was found in the 5′
UTR. The sequence, which extended into the 3′ non-
coding region, did not contain the polyadenylation sig-
nal. The protein encoded by the human CAC cDNA
contains 301 amino acids, and its calculated molecular
weight is 32.9 kD.
Expression of CAC mRNA in Human Tissues
A hybridization probe consisting of nucleotides
421–967 of the human liver CAC cDNA was employed
in northern blot experiments. Figure 2 shows the pres-
ence of one band for CAC mRNA, ∼1.8 kb in length,
in various human tissue types. The CAC mRNA was
highly expressed in heart, skeletal muscle, and liver tis-
sues. A much lower level of expression was found in
brain, placental, pancreatic, and kidney tissues and es-
pecially in lung tissue. These differences in the level of
expression of the CAC transcript in the various tissues
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Table 1
Overall b-Oxidation Rates and CAC Activities in Cultured
Skin Fibroblasts of the Patient and of Controls
Patient Controls (n)a
Overall b-oxidation (nmol/h/mg):
[9,10-3H]Myristic acid 4.1 6.0  2.3 (61)
[9,10-3H]Palmitic acid 2.4 8.8  4.1 (33)
CAC activity (pmol/min/mg):
Produced 14CO2 ND
b 47  16 (5)
a Data are the mean  SD. n  no. of controls.
b ND  not detectable.
Figure 3 Sequences of CAC cDNA segments, with their accom-
panying amino acid codes, for a control (wild type) (A) and the patient
(B). For the patient, a C insertion, resulting in a frameshift and an
extension of the C terminus of the CAC protein (underlined), is shown
(arrow).
tested were not due to variations in the amounts of RNA
loaded on the gel, since this was checked in a control
experiment with an actin probe.
Biochemical Studies in the Index Patient
Biochemical measurements of intact cultured skin fi-
broblasts showed a diminished oxidation rate of 3H-
labeled myristic and palmitic acid (66% and 27%, re-
spectively, of the control mean), as shown in table 1.
The oxidation rate of 14C-labeled octanoate and butyrate
was found to be normal (not shown). The activities of
the various mitochondrial fatty acyl-CoA dehydrogen-
ases, the enoyl-CoA hydratases, the 3-hydroxyacyl-CoA
dehydrogenases, and the 3-ketoacyl-CoA thiolases, as
well as of carnitine palmitoyltransferases I and II, were
all normal (not shown). As shown in table 1, the activity
of CAC was not detectable.
Mutation Analysis
The CAC mRNA from cultured skin fibroblasts from
the patient was reverse transcribed, and the cDNA was
PCR amplified in three overlapping fragments. Sequenc-
ing of these fragments revealed an insertion of a cytosine
in the cytosine-rich region of bp 955–959, as shown in
figure 3. This insertion changes the sequence of the CAC
protein from amino acid 300 (asparagine to glutamine)
to the carboxy terminus and expands the length of the
protein by 21 amino acids, to 322 amino acids (fig. 4A).
Hydrophilicity calculations were performed according
to the Kyte-Doolittle method, for the peptide sequence
of the wild-type and the patient’s CAC. The values ob-
tained were used for Chou-Fasman predictions of the
secondary structure of the protein. The Chou-Fasman
two-dimensional plot (fig. 4B) showed a dramatic con-
formational change, at the C-terminal region, between
the wild-type and the patient’s CAC protein.
Discussion
Primary Structure of Human CAC
The protein encoded by the human CAC gene is 301
amino acids long, and its calculated molecular weight is
32.9 kD. The amino acid sequences of human and rat
CAC are highly conserved: there is ∼90% identity be-
tween these species (fig. 1) (Indiveri et al. 1997). Human
CAC differs from its rat counterpart in 29 amino acids,
15 of which are nonconserved. The identity between the
human and rat CAC is less than that found for some
other mitochondrial carriers. In fact, 97% identity was
found between the human and rat 2-oxoglutarate car-
riers (Iacobazzi et al. 1992; Dolce et al. 1994b), and
95% identity was found between the human and rat
citrate carriers (Kaplan et al. 1993; Iacobazzi et al. 1997)
and phosphate carriers (Ferreira et al. 1989; Dolce et al.
1994a). Three repeated homologous domains, each
∼100 amino acids in length, can be distinguished in the
human CAC, a characteristic previously recognized in
other mitochondrial transport proteins (Walker and
Runswick 1993; Palmieri 1994). These domains are re-
lated to those found in the mitochondrial carrier-protein
family (Walker and Runswick 1993; Palmieri 1994).
The cDNA and deduced protein sequences are in
GenBank (accession no. Y10319; http://www.ncbi.nhm
.nih.gov/Web/Genbank/index.htm). A Blast search for
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Figure 4 A, Primary C-terminal amino acid sequence of wild-type (top) and patient’s (bottom) CAC protein. B, Predicted secondary
structure, according to the Chou-Fasman algorithm, of wild-type (top) and patient’s elongated (bottom) CAC.
homologous sequences revealed seven different ex-
pressed-sequence-tag (EST) clones (AA305590,R11780,
F08483, Z28872, AA378439, N77642, and N87428)
that originated from different human tissues. These EST
clones have sequences that are homologous with differ-
ent parts of the CAC protein and are presumed to encode
a carrier protein of unknown function.
Tissue Distribution of CAC mRNA
The CAC defect was detected in the patient’s fibro-
blasts. It is likely that CAC deficiency occurs in all tis-
sues, since no evidence for the existence of various tissue-
specific isoforms has been found. As shown in figure 2,
high levels of CAC mRNA transcripts were found in
heart, skeletal muscle, and liver tissues, which is in fair
agreement with the clinical involvement of these tissues
in the patient. Much lower levels of expression were
found in brain, placental, kidney, and pancreatic tissues
and especially in lung tissue.
CAC-Deficient Patient
We have identified CAC deficiency in cultured skin
fibroblasts from a child who survived a stormy neonatal
period due to her fatty-acid oxidation disorder, which
invariably has been fatal in other patients (Stanley et al.
1992; Pande et al. 1993; Brivet et al. 1994, 1996; Ni-
ezen-Koning et al. 1995; Ogier de Baulney et al. 1995).
Direct sequencing of the entire cDNA of the patient re-
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vealed the presence of a homozygous insertion of a cy-
tosine nucleotide in the only cytosine-containing region,
bp 955–959, resulting in a frameshift. We repeated se-
quencing of the cDNA of this patient and of three con-
trols, in three independent experiments, all of which re-
vealed the homozygous insertion in the patient’s cDNA.
This excludes the possibility of a mistake made by the
Taq DNA polymerase in the PCR reaction. The region
containing the insertion consists of five cytosine nucle-
otides, which makes confirmation of the insertion by
restriction-enzyme analysis impossible. Unfortunately,
no material from the other family memberswas available
for further investigations.
The CAC protein of the patient has an obviously
changed C terminus: amino acids 300 and 301 are
changed from asparagine and leucine, respectively, to
glutamine and leucine, respectively, and the protein has
been elongated by 21 amino acids. A Chou-Fasman pre-
diction shows a dramatically changed secondary struc-
ture. The C terminus is changed from a turn (in wild-
type CAC) to a helix structure, in the patient. The
molecular basis of the transport process mediated by the
CAC is still unrevealed. A proper folding and orientation
of the CAC protein in the mitochondrial membrane is
crucial for adequate functioning. The novel extension in
the patient contains a hydrophobic domain, which may
be embedded in the mitochondrial inner membrane in-
stead of protruding into the intermembrane space. A
diminished entrapping or binding capacity of the posi-
tive charge of the quaternary nitrogen of carnitine to the
negative carboxylate of the CAC C-terminus can be hy-
pothesized for the patient. The alterations of the pa-
tient’s CAC also may lead to instability of the protein.
An impairment of the patient’s CAC in substrate binding
or translocation also can be considered. The functional
consequences of the molecular defect apparently are re-
stricted, in view of the mild clinical phenotype of the
patient. Surprisingly, no CAC activity was detectable in
fibroblasts.
In the present study, we determined the sequence of
the human cDNA of the mitochondrial CAC, showed
differences in human tissue distribution, and defined the
first molecular defect in a CAC-deficient patient. This
study provides the techniques necessary to resolve the
molecular basis of CAC deficiency. This may be of great
importance for the reliable diagnosis of patients at risk
and also may guide the way toward prenatal diagnosis
of this severe type of inborn error in metabolism.
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